These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7888107)

  • 21. A controlled trial of piracetam in intellectually impaired patients with Parkinson's disease.
    Sano M; Stern Y; Marder K; Mayeux R
    Mov Disord; 1990; 5(3):230-4. PubMed ID: 2388639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A double-blind investigation of piracetam (nootropil) versus placebo in the memory of geriatric inpatients.
    Abuzzahab FS; Merwin GE; Zimmermann RL; Sherman MC
    Psychopharmacol Bull; 1978 Jan; 14(1):23-5. PubMed ID: 343146
    [No Abstract]   [Full Text] [Related]  

  • 23. [Piracetam--a drug for decreasing potency?].
    Hofmann N
    Med Welt; 1978 Jun; 29(26):1096-9. PubMed ID: 672574
    [No Abstract]   [Full Text] [Related]  

  • 24. Piracetam in alcoholic psychoses: a double-blind, crossover, placebo controlled study.
    Skondia V; Kabes J
    J Int Med Res; 1985; 13(3):185-7. PubMed ID: 3891457
    [No Abstract]   [Full Text] [Related]  

  • 25. [The effect of piracetam on involuntary movements in Huntington's disease. A double-blind, placebo-controlled study].
    Mateo D; Giménez-Roldán S
    Neurologia; 1996 Jan; 11(1):16-9. PubMed ID: 8714171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy of piracetam in vertigo. A double-blind study in patients with vertigo of central origin.
    Oosterveld WJ
    Arzneimittelforschung; 1980; 30(11):1947-9. PubMed ID: 7006617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Piracetam--an old drug with novel properties?
    Winnicka K; Tomasiak M; Bielawska A
    Acta Pol Pharm; 2005; 62(5):405-9. PubMed ID: 16459490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Management of neuroleptic side-effects with piracetam (author's transl)].
    Sikora J; Kabes J; Pisvejc J
    Cesk Psychiatr; 1981 Apr; 77(2):137-42. PubMed ID: 6114800
    [No Abstract]   [Full Text] [Related]  

  • 29. [Drug therapy of Alzheimer's disease. Problems of the criteria of clinical trials of nootropic drugs].
    Hirai S
    Nihon Rinsho; 1988 Jul; 46(7):1592-9. PubMed ID: 3221466
    [No Abstract]   [Full Text] [Related]  

  • 30. [Effect of piracetam on the brain-organic psychosyndrome in cerebrovascular insufficiency. Results of a double-blind study in 40 cases].
    Trabant R; Poljakovic Z; Trabant D
    Ther Ggw; 1977 Aug; 116(8):1504-21. PubMed ID: 331549
    [No Abstract]   [Full Text] [Related]  

  • 31. [Piracetam in premature biological aging. Double-blind study after preselection by drugs].
    Dorn M
    Fortschr Med; 1978 Aug; 96(30):1525-30. PubMed ID: 669550
    [No Abstract]   [Full Text] [Related]  

  • 32. [Treatment of vertigo syndrome with Nootropil].
    Miszke A; Rapacz K
    Otolaryngol Pol; 1988; 42(5):312-7. PubMed ID: 3075732
    [No Abstract]   [Full Text] [Related]  

  • 33. A double-blind, placebo-controlled study of piracetam in elderly psychiatric patients [proceedings].
    Chouinard G; Annable L; Ross-Chouinard A; Olivier M; Fontaine F
    Psychopharmacol Bull; 1981 Jan; 17(1):129. PubMed ID: 7232645
    [No Abstract]   [Full Text] [Related]  

  • 34. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.
    Burns A; Gauthier S; Perdomo C
    Int J Geriatr Psychiatry; 2007 Aug; 22(8):806-12. PubMed ID: 17199235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial.
    Scarpini E; Bruno G; Zappalà G; Adami M; Richarz U; Gaudig M; Jacobs A; Schäuble B
    J Alzheimers Dis; 2011; 26(2):211-20. PubMed ID: 21606568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological treatment of Alzheimer's disease in the population of Catalonia, Spain.
    Obach M; Lopez P; Catalan A
    Med Clin (Barc); 2017 Jul; 149(2):86-87. PubMed ID: 28527596
    [No Abstract]   [Full Text] [Related]  

  • 37. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results.
    Amenta F; Carotenuto A; Fasanaro AM; Rea R; Traini E
    J Neurol Sci; 2012 Nov; 322(1-2):96-101. PubMed ID: 22959283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quality of Life and Utility Measurement in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer's Disease: Determinants and Level of Changes Observed.
    Lacey L; Bobula J; Rüdell K; Alvir J; Leibman C
    Value Health; 2015 Jul; 18(5):638-45. PubMed ID: 26297092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter, extension study in Japan.
    Homma A; Imai Y; Tago H; Asada T; Shigeta M; Iwamoto T; Takita M; Arimoto I; Koma H; Takase T; Ohbayashi T
    Dement Geriatr Cogn Disord; 2009; 27(3):232-9. PubMed ID: 19246907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The SERAD study of the safety and efficacy of galantamine in severe Alzheimer's disease.
    Farlow MR
    Lancet Neurol; 2009 Jan; 8(1):22-3. PubMed ID: 19042160
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.